Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with ...
That's the audience that the London Business School is targeting with a new one-year MBA program. Unlike a traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results